News articles

• 

  Blood Tests: Not Just for the Impaired?

  In memory clinics and in research cohorts, immunoassays for plasma markers can now distinguish people who have Alzheimer’s disease... Read more...

• Looking Good: Immunoassays for Blood Markers

  For years, scientists have been working toward blood tests for Alzheimer’s disease that could be used routinely in clinical... Read more...
• 

  More opportunities to test for Alzheimer’s using new analytical method

  A simpler method of analysing blood samples for Alzheimer’s disease has been tested in a large multicentre study, led... Read more...
• 

  Simple, yet effective way to early detect Alzheimer’s disease

  A simpler method of analysing blood samples for Alzheimer’s disease has been tested in a large multicentre study, led... Read more...
• 

  How dementia affects the brain’s ability to empathize

  Patients with frontotemporal dementia often lack the ability to feel empathy. A study at Lund University and the Karolinska... Read more...
• 

  Reading the signs of dementia

  In this Nature outlook the BioFINDER study group’s work on how blood tests are leading to earlier diagnosis, and... Read more...

Recent key publications

• Plasma phospho-tau217 for Alzheimer’s disease diagnosis in primary and secondary care using a fully automated platform

• Plasma MTBR-tau243 biomarker identifies tau tangle pathology in Alzheimer’s disease

• Plasma p-tau217 and tau-PET predict future cognitive decline among cognitively unimpaired individuals: implications for clinical trials

• Machine learning prediction of tau‐PET in Alzheimer’s disease using plasma, MRI, and clinical data

• Alpha-synuclein seed amplification assay longitudinal outcomes in Lewy body disease spectrum.

• Altered Empathy Processing in Frontotemporal Dementia.

• Diagnosis of Alzheimer’s disease using plasma biomarkers adjusted to clinical probability.

• A comprehensive head-to-head comparison of key plasma phosphorylated tau 217 biomarker tests.

• Lewy body pathology exacerbates brain hypometabolism and cognitive decline in Alzheimer’s disease.

• Blood Biomarkers to Detect Alzheimer Disease in Primary Care and Secondary Care

• Plasma Phosphorylated Tau 217 and Aβ42/40 to Predict Early Brain Aβ Accumulation in People Without Cognitive Impairment

• MRI Signature of α-Synuclein Pathology in Asymptomatic Stages and a Memory Clinic Population

• Revised criteria for the diagnosis and staging of Alzheimer’s disease

• Disease progression modelling reveals heterogeneity in trajectories of Lewy-type α-synuclein pathology

• Tau Positron Emission Tomography for Predicting Dementia in Individuals With Mild Cognitive Impairment

• Disease staging of Alzheimer’s disease using a CSF-based biomarker model

• A blood-based biomarker workflow for optimal tau-PET referral in memory clinic settings

• Highly Accurate Blood Test for Alzheimer’s Disease Comparable or Superior to Clinical CSF Tests.

• Plasma Biomarker Strategy for Selecting Patients With Alzheimer Disease for Antiamyloid Immunotherapies.

• The α-synuclein PET tracer [18F] ACI-12589 distinguishes multiple system atrophy from other neurodegenerative diseases.

• DOPA decarboxylase is an emerging biomarker for Parkinsonian disorders including preclinical Lewy body disease.

• Cognitive effects of Lewy body pathology in clinically unimpaired individuals.

• Clinical effects of Lewy body pathology in cognitively impaired individuals.

• CSF MTBR-tau243 is a specific biomarker of tau tangle pathology in Alzheimer’s disease.

X posts

BioFINDER @biofinder_study ·

13h 1927662861226033281

🚨Exciting new preprint from a great collaboration between our group and the talented PhD student @jorittmo from @_JakeVogel_'s group! They investigate how the 🧠 reorganises in the context of age and AD. Dive into the details here 🧵👇

Twitter feed video.

Jonathan Rittmo @jorittmo

How does the brain reorganize in the context of age and AD?

Are functional changes in age and AD similar?

Are these changes dynamic across the age/AD spectrum?

We unpack these questions in a sample of N=973 with AD biomarkers

Preprint: http://tinyurl.com/ymv8s7h8

1/
⬇️🧵

Reply on Twitter 1927662861226033281 Retweet on Twitter 1927662861226033281 1 Like on Twitter 1927662861226033281 5 X 1927662861226033281

Retweet on Twitter BioFINDER Retweeted

Emma Coomans @EmmaCoomans ·

28 Apr 1916902776279384354

So excited and honored to be invited to present the opening plenary at #AIC2025 this year in Toronto! 🧠

🙏 I would be very grateful if you could help me gather the most inspiring papers (including your own!) of the past year by completing this survey:

Reply on Twitter 1916902776279384354 Retweet on Twitter 1916902776279384354 10 Like on Twitter 1916902776279384354 29 X 1916902776279384354

Retweet on Twitter BioFINDER Retweeted

Nicholas Ashton @NicholasAshton ·

1 May 1917795053910778310

Immunoassay choice for #pTau217 is important!

In this study, we show that LMW #pTau217 is more specific to Alzheimers pathology than HMW #pTau217 immunoassay designs – which can give false-positives.



@biofinder_study @OskarHansson9

Reply on Twitter 1917795053910778310 Retweet on Twitter 1917795053910778310 9 Like on Twitter 1917795053910778310 31 X 1917795053910778310

BioFINDER @biofinder_study ·

5 May 1919368003273073114

🚨New paper in Alzheimer's & Dementia! We investigate whether p-tau immuno-assays selectively quantifying low-molecular-weight (LMW) tau (CNS) are more specific for tau changes in AD vs ALS than assays not differentiating between LMW and high-MW (PNS) tau👇

A comparison of p‐tau assays for the specificity to detect tau changes in Alzheimer's disease

We evaluated differences in p‐tau levels between Alzheimer's disease (AD), a condition with brain‐specific changes i...

pmc.ncbi.nlm.nih.gov

Show Thread

Reply on Twitter 1919368003273073114 Retweet on Twitter 1919368003273073114 6 Like on Twitter 1919368003273073114 14 X 1919368003273073114

BioFINDER @biofinder_study ·

5 May 1919368015101018142

6/🧵Concluding, plasma assays specific for LMW p-tau are preferable in the diagnostic workup of AD, with fewer false positive findings, especially in diverse population-based communities where peripheral neuropathy may produce high p-tau levels when using non-LMW specific assays.

Reply on Twitter 1919368015101018142 Retweet on Twitter 1919368015101018142 0 Like on Twitter 1919368015101018142 0 X 1919368015101018142

BioFINDER @biofinder_study ·

5 May 1919368846424543526

A big thank you to all our collaborators from Bologna, Umeå, and Gothenburg and a special thanks to all co-authors @NicholasAshton @A_OrdunaDolado @DivyaBali06 @NiklasMattsson4 @OskarHansson9
and all not on X!

Reply on Twitter 1919368846424543526 Retweet on Twitter 1919368846424543526 0 Like on Twitter 1919368846424543526 0 X 1919368846424543526

BioFINDER @biofinder_study ·

25 Apr 1915697149515334122

‼️New preprint!

We are happy to share our latest work led by @teanijarv investigating why tau pathology in Alzheimer’s disease (AD) often accumulates more in one hemisphere of the brain than the other.

Check out🔗 or dive into the details below👇

Hemispheric Asymmetry of Tau Pathology is Related to Asymmetric Amyloid Deposition in Alzheimer’s...

The distribution of tau pathology in Alzheimer’s disease (AD) shows remarkable inter-individual heterogeneity, including ...

www.biorxiv.org

Show Thread

Reply on Twitter 1915697149515334122 Retweet on Twitter 1915697149515334122 13 Like on Twitter 1915697149515334122 22 X 1915697149515334122

BioFINDER @biofinder_study ·

25 Apr 1915697558480970084

6/🧵Our findings suggest that regional vulnerability to Aβ, not reduced inter-hemispheric connectivity, drives asymmetric tau accumulation in AD. This strengthens the link between Aβ and tau and supports the evidence of early anti-Aβ interventions to help limit tau buildup.

Reply on Twitter 1915697558480970084 Retweet on Twitter 1915697558480970084 1 Like on Twitter 1915697558480970084 3 X 1915697558480970084

BioFINDER @biofinder_study ·

25 Apr 1915697560192258150

Big thanks to all co-authors and collaborators!
@RikOssenkoppele @ErikRubenSmith @LECollij @aitchbi @jorittmo @karlssonlinda1 @DaniellevWe @_JakeVogel_ @EStomrud @SebastianPalmqv @NiklasMattsson4 @NicolaSpotorno @OskarHansson9 + those not on X

Reply on Twitter 1915697560192258150 Retweet on Twitter 1915697560192258150 1 Like on Twitter 1915697560192258150 3 X 1915697560192258150

BioFINDER @biofinder_study ·

24 Apr 1915382516069851550

🧠Exciting new findings from a great collaboration between the BioFINDER study and the talented @xiaoyucaly from @_JakeVogel_ group!! In their preprint, they show that tau presence and tau load are guided by unique brain mechanisms. Dive into the details here 👇

Caly Yu Xiao (肖燏) @xiaoyucaly

🧠New preprint alert! Tau, the pathological protein in AD, spreads through the brain in a very particular pattern. But what drives this pattern?

We found that WHERE tau pathology appears, and HOW MUCH accumulates there, are governed by different mechanisms. Check out our…

Reply on Twitter 1915382516069851550 Retweet on Twitter 1915382516069851550 4 Like on Twitter 1915382516069851550 10 X 1915382516069851550

BioFINDER @biofinder_study ·

24 Apr 1915380264999571849

Our research on altered empathy processing in frontotemporal dementia was recently featured in The Conversation! Great to see this important work reaching a wider audience.
🔗
📖Check out the original publication 👇

BioFINDER @biofinder_study

🚨Paper alert🚨
New publication lead by Alexander Santillo in @JAMANeuro : Altered Empathy Processing in Frontotemporal Dementia

https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2827334?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=120324

Reply on Twitter 1915380264999571849 Retweet on Twitter 1915380264999571849 2 Like on Twitter 1915380264999571849 5 X 1915380264999571849

BioFINDER @biofinder_study ·

15 Apr 1912049586350235887

🚨New paper alert! Research from our group and collaborators at @UniMelb shows increased speed of neuronal aging in schizophrenia- the same phenomena was not seen in bipolar disorder. 📖Read more here:

Brains of people with schizophrenia may age faster – how our research adds to the evidence

Study suggests accelerated brain ageing is a factor in the development of schizophrenia – and can be measured using a simple blood test.

theconversation.com

Reply on Twitter 1912049586350235887 Retweet on Twitter 1912049586350235887 3 Like on Twitter 1912049586350235887 5 X 1912049586350235887

BioFINDER @biofinder_study ·

20 Dec 1870018117578920035

The BioFINDER group wishes you happy holidays!🎄

Twitter feed image.

Reply on Twitter 1870018117578920035 Retweet on Twitter 1870018117578920035 4 Like on Twitter 1870018117578920035 26 X 1870018117578920035

Retweet on Twitter BioFINDER Retweeted

Oskar Hansson @OskarHansson9 ·

18 Nov 1858623327553946040

I was very grateful to meet the former Swedish prime minister Ingvar Carlsson today. He told about his experiences in taking care of his wife with Alzheimer’s disease for the last decade. He is such a fantastic and kind person! And still going strong when 90 years old.

Twitter feed image.

Reply on Twitter 1858623327553946040 Retweet on Twitter 1858623327553946040 5 Like on Twitter 1858623327553946040 49 X 1858623327553946040

Retweet on Twitter BioFINDER Retweeted

Michael Okun @MichaelOkun ·

31 Oct 1851993297046376515

Which p-tau 217 assay for Alzheimer's was the best in comparative testing? This question is becoming an increasingly important one, as p-tau 217 has emerged as a possible single test which has great value. Noëlle Warmenhoven shares results in a fresh collaborative @Brain1878…

Twitter feed image.

Reply on Twitter 1851993297046376515 Retweet on Twitter 1851993297046376515 16 Like on Twitter 1851993297046376515 50 X 1851993297046376515

Load More